154 related articles for article (PubMed ID: 38378030)
21. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
[TBL] [Abstract][Full Text] [Related]
22. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Holleman A; Cheok MH; den Boer ML; Yang W; Veerman AJ; Kazemier KM; Pei D; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
N Engl J Med; 2004 Aug; 351(6):533-42. PubMed ID: 15295046
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia.
Boris E; Theron A; Montagnon V; Rouquier N; Almeras M; Moreaux J; Bret C
Cytometry B Clin Cytom; 2024 Jan; 106(1):45-57. PubMed ID: 38037221
[TBL] [Abstract][Full Text] [Related]
24. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
25. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia.
Holleman A; den Boer ML; Kazemier KM; Janka-Schaub GE; Pieters R
Blood; 2003 Dec; 102(13):4541-6. PubMed ID: 12920041
[TBL] [Abstract][Full Text] [Related]
26. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
Hallböök H; Barbany G; Aleskog A; Björnberg A; Larsson R; Sundström C; Lindhagen E
Anticancer Drugs; 2005 Jul; 16(6):631-4. PubMed ID: 15930891
[TBL] [Abstract][Full Text] [Related]
29. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Dworzak MN; Schumich A; Printz D; Pötschger U; Husak Z; Attarbaschi A; Basso G; Gaipa G; Ratei R; Mann G; Gadner H
Blood; 2008 Nov; 112(10):3982-8. PubMed ID: 18780832
[TBL] [Abstract][Full Text] [Related]
30. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
[TBL] [Abstract][Full Text] [Related]
31. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
[TBL] [Abstract][Full Text] [Related]
32. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.
Czuczman MS; Dodge RK; Stewart CC; Frankel SR; Davey FR; Powell BL; Szatrowski TP; Schiffer CA; Larson RA; Bloomfield CD
Blood; 1999 Jun; 93(11):3931-9. PubMed ID: 10339502
[TBL] [Abstract][Full Text] [Related]
33. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
[TBL] [Abstract][Full Text] [Related]
35. Treatment of high-risk acute lymphoblastic leukemia with protocols PETHEMA LAL 7/78 and LAL 17/84.
Ortega JJ; Javier G; Olivé T
An Esp Pediatr; 1988 Oct; 29 Suppl 34():72-83. PubMed ID: 3214043
[No Abstract] [Full Text] [Related]
36. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
37. Infusion of anti-CD10 monoclonal antibody (J5) following ablative chemotherapy in a patient with refractory pre-B acute lymphoblastic leukemia.
Ruiz-Argüelles GJ; Ruiz-Argüelles A; Lobato-Mendizábal E; Presno-Bernal M; Alvarez-Amaya C
Rev Invest Clin; 1991; 43(3):259-63. PubMed ID: 1840161
[TBL] [Abstract][Full Text] [Related]
38. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.
Dworzak MN; Gaipa G; Schumich A; Maglia O; Ratei R; Veltroni M; Husak Z; Basso G; Karawajew L; Gadner H; Biondi A
Cytometry B Clin Cytom; 2010 May; 78(3):147-53. PubMed ID: 20201055
[TBL] [Abstract][Full Text] [Related]
39. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
40. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
